{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:09:44Z","timestamp":1793383784820,"version":"4.5.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s11912-022-01310-3","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T06:02:51Z","timestamp":1660111371000},"page":"1489-1499","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Management of Peripheral T-cell Lymphomas and the Role of Transplant"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3862-0232","authenticated-orcid":false,"given":"Nicole C.","family":"Foley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5744-0670","authenticated-orcid":false,"given":"Neha","family":"Mehta-Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"1310_CR1","doi-asserted-by":"publisher","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood [Internet]. 2016 [cited 2021 Dec 12];127:2375\u201390. Available from: https:\/\/doi.org\/10.1182\/blood-2016-01-643569","DOI":"10.1182\/blood-2016-01-643569"},{"key":"1310_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.clml.2016.10.001","volume":"17","author":"ED Hsi","year":"2017","unstructured":"Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, et al. Analysis of peripheral T-cell lymphoma diagnostic workup in the United States. Clin Lymphoma Myeloma Leuk. 2017;17:193\u2013200.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1310_CR3","doi-asserted-by":"crossref","unstructured":"Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin\u2019s lymphomas: distributions of the major subtypes differ by geographic locations. Annals of Oncology [Internet]. Elsevier; 1998 [cited 2022 Mar 16];9:717\u201320. Available from: https:\/\/www.annalsofoncology.org\/article\/S0923-7534(19)55920-8\/fulltext","DOI":"10.1023\/A:1008265532487"},{"key":"1310_CR4","doi-asserted-by":"crossref","unstructured":"Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124\u201330.","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"1310_CR5","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s12185-014-1520-3","volume":"99","author":"S Park","year":"2014","unstructured":"Park S, Ko YH. Peripheral T cell lymphoma in Asia. Int J Hematol. 2014;99:227\u201339.","journal-title":"Int J Hematol"},{"key":"1310_CR6","doi-asserted-by":"crossref","unstructured":"de Leval L, Parrens M, Le Bras F, Jais J-P, Fataccioli V, Martin A, et al. Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. Haematologica [Internet]. 2015 [cited 2022 Mar 19];100:e361\u20134. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4800690\/","DOI":"10.3324\/haematol.2015.126300"},{"key":"1310_CR7","doi-asserted-by":"crossref","unstructured":"Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, et al. A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. Cancer [Internet]. 2017 [cited 2022 Mar 15];123:1174\u201383. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5650190\/","DOI":"10.1002\/cncr.30416"},{"key":"1310_CR8","doi-asserted-by":"publisher","unstructured":"M.A. Shipp. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. NEJM [Internet]. Massachusetts Medical Society; 1993;329:987\u201394. Available from: https:\/\/doi.org\/10.1056\/NEJM199309303291402","DOI":"10.1056\/NEJM199309303291402"},{"key":"1310_CR9","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","volume":"103","author":"A Gallamini","year":"2004","unstructured":"Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474\u20139.","journal-title":"Blood"},{"key":"1310_CR10","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","volume":"24","author":"P Went","year":"2006","unstructured":"Went P, Agostinelli C, Gallamini A, Piccaluga PP, Ascani S, Sabattini E, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24:2472\u20139.","journal-title":"J Clin Oncol"},{"key":"1310_CR11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V106.11.811.811","author":"Vose JM, The International PTCL Project. International Peripheral T-Cell Lymphoma (PTCL) clinical and pathologic review project: poor outcome by prognostic indices and lack of efficacy with anthracyclines. Blood [Internet]","year":"2005","unstructured":"Vose JM, The International PTCL Project. International Peripheral T-Cell Lymphoma (PTCL) clinical and pathologic review project: poor outcome by prognostic indices and lack of efficacy with anthracyclines. Blood [Internet]. [cited 2022 Mar 26];106:811. Available from. 2005. https:\/\/doi.org\/10.1182\/blood.V106.11.811.811.","journal-title":"Available from"},{"key":"1310_CR12","doi-asserted-by":"publisher","unstructured":"Federico M, Bellei M, Marcheselli L, Schwartz M, Manni M, Tarantino V, et al. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. British Journal of Haematology [Internet]. 2018 [cited 2022 Mar 22];181:760\u20139. Available from: https:\/\/doi.org\/10.1111\/bjh.15258","DOI":"10.1111\/bjh.15258"},{"key":"1310_CR13","doi-asserted-by":"crossref","unstructured":"Guti\u00e9rrez-Garc\u00eda G, Garc\u00eda-Herrera A, Cardesa T, Mart\u00ednez A, Villamor N, Ghita G, et al. Comparison of four prognostic scores in peripheral T-cell lymphoma. Annals of Oncology [Internet]. Elsevier; 2011 [cited 2022 Mar 26];22:397\u2013404. Available from: https:\/\/www.annalsofoncology.org\/article\/S0923-7534(19)38661-2\/fulltext","DOI":"10.1093\/annonc\/mdq359"},{"key":"1310_CR14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/j.seminhematol.2021.02.001","volume":"58","author":"M-K Malecek","year":"2021","unstructured":"Malecek M-K, Mehta-Shah N. Prognosis and risk stratification of peripheral T-cell lymphomas. Semin Hematol. 2021;58:70\u20137.","journal-title":"Semin Hematol"},{"key":"1310_CR15","doi-asserted-by":"crossref","unstructured":"Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Annals of Oncology [Internet]. Elsevier; 2004 [cited 2022 Mar 15];15:1467\u201375. Available from: https:\/\/www.annalsofoncology.org\/article\/S0923-7534(19)51047-X\/fulltext","DOI":"10.1093\/annonc\/mdh392"},{"key":"1310_CR16","doi-asserted-by":"publisher","unstructured":"Ellin F, Landstr\u00f6m J, Jerkeman M, Relander T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood [Internet]. 2014 [cited 2022 Mar 15];124:1570\u20137. Available from:https:\/\/doi.org\/10.1182\/blood-2014-04-573089","DOI":"10.1182\/blood-2014-04-573089"},{"key":"1310_CR17","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","volume":"111","author":"KJ Savage","year":"2008","unstructured":"Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008;111:5496\u2013504.","journal-title":"Blood"},{"key":"1310_CR18","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d\u2019Amore","year":"2012","unstructured":"d\u2019Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012;30:3093\u20139.","journal-title":"J Clin Oncol"},{"key":"1310_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Illidge T, Fanale M, Advani R, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393:229\u201340.","journal-title":"Lancet"},{"key":"1310_CR20","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.annonc.2021.12.002","volume":"33","author":"S Horwitz","year":"2022","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, Tr\u00fcmper L, Iyer S, Advani R, et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol. 2022;33:288\u201398.","journal-title":"Ann Oncol"},{"key":"1310_CR21","doi-asserted-by":"publisher","unstructured":"Schmitz N, Tr\u00fcmper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood [Internet]. 2010 [cited 2022 Mar 15];116:3418\u201325. Available from: https:\/\/doi.org\/10.1182\/blood-2010-02-270785","DOI":"10.1182\/blood-2010-02-270785"},{"key":"1310_CR22","doi-asserted-by":"publisher","unstructured":"Altmann B, Wulf G, Truemper L, d\u2019Amore F, Relander T, Toldbod H, et al. Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (PTCL) in previously untreated young and elderly patients: pooled analysis of the international ACT-1\/2 phase III trials. Blood [Internet]. 2018 [cited 2022 Mar 27];132:1622. Available from: https:\/\/doi.org\/10.1182\/blood-2018-99-112076","DOI":"10.1182\/blood-2018-99-112076"},{"key":"1310_CR23","doi-asserted-by":"crossref","unstructured":"Bachy E, Camus V, Thieblemont C, Casasnovas R-O, Ysebaert L, Damaj GL, et al. Final analysis of the Ro-CHOP phase III study (conducted by LYSA): romidepsin plus CHOP in patients with peripheral T-cell lymphoma. Blood [Internet]. American Society of Hematology; 2020 [cited 2022 Apr 5];136:32\u20133. Available from: http:\/\/ashpublications.org\/blood\/article\/136\/Supplement 1\/32\/469958\/Final-Analysis-of-the-Ro-CHOP-Phase-III-Study","DOI":"10.1182\/blood-2020-134440"},{"key":"1310_CR24","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/bjh.13855","volume":"172","author":"RH Advani","year":"2016","unstructured":"Advani RH, Ansell SM, Lechowicz MJ, Beaven AW, Loberiza F, Carson KR, et al. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial. Br J Haematol. 2016;172:535\u201344.","journal-title":"Br J Haematol"},{"key":"1310_CR25","doi-asserted-by":"publisher","unstructured":"Lunning MA, Horwitz SM, Advani R, Vose JM, Lee HJ, Mehta-Shah N, et al. Phase I\/II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-Cell lymphoma: phase II results. Blood [Internet]. 2018 [cited 2022 Mar 27];132:2899. Available from:https:\/\/doi.org\/10.1182\/blood-2018-99-114110","DOI":"10.1182\/blood-2018-99-114110"},{"issue":"Suppl 5","key":"1310_CR26","doi-asserted-by":"publisher","first-page":"v108","DOI":"10.1093\/annonc\/mdv201","volume":"26","author":"F d\u2019Amore","year":"2015","unstructured":"d\u2019Amore F, Gaulard P, Tr\u00fcmper L, Corradini P, Kim W-S, Specht L, et al. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v108-115.","journal-title":"Ann Oncol"},{"key":"1310_CR27","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1016\/j.bbmt.2017.07.027","volume":"23","author":"MA Kharfan-Dabaja","year":"2017","unstructured":"Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, et al. Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK\/T cell lymphomas: an international collaborative effort on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017;23:1826\u201338.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1310_CR28","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer P, R\u00fcdiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009;27:106\u201313.","journal-title":"J Clin Oncol"},{"key":"1310_CR29","doi-asserted-by":"crossref","unstructured":"Wilhelm M, Smetak M, Reimer P, Geissinger E, Ruediger T, Metzner B, et al. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. Blood Cancer Journal [Internet]. Nature Publishing Group; 2016 [cited 2022 Mar 14];6:e452\u2013e452. Available from: https:\/\/www.nature.com\/articles\/bcj201663","DOI":"10.1038\/bcj.2016.63"},{"key":"1310_CR30","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Sancho AM, Bellei M, L\u00f3pez-Parra M, Gritti G, Cort\u00e9s M, Novelli S, et al. Autologous stem cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO\/FIL study. Haematologica. 2022;","DOI":"10.3324\/haematol.2021.279426"},{"key":"1310_CR31","doi-asserted-by":"crossref","unstructured":"Savage KJ, Horwitz SM, Advani RH, Christensen JH, Domingo-Domenech E, Rossi G, et al. An exploratory analysis of brentuximab vedotin plus CHP (A+CHP) in the frontline treatment of patients with CD30+ peripheral T-cell lymphomas (ECHELON-2): impact of consolidative stem cell transplant. Blood [Internet]. American Society of Hematology; 2019 [cited 2022 Apr 5];134:464\u2013464. Available from: http:\/\/ashpublications.org\/blood\/article\/134\/Supplement_1\/464\/426343\/An-Exploratory-Analysis-of-Brentuximab-Vedotin","DOI":"10.1182\/blood-2019-122781"},{"key":"1310_CR32","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/cncr.31861","volume":"125","author":"SI Park","year":"2019","unstructured":"Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019;125:1507\u201317.","journal-title":"Cancer"},{"key":"1310_CR33","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/annonc\/mdx787","volume":"29","author":"G Fossard","year":"2018","unstructured":"Fossard G, Broussais F, Coelho I, Bailly S, Nicolas-Virelizier E, Toussaint E, et al. Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers. Ann Oncol. 2018;29:715\u201323.","journal-title":"Ann Oncol"},{"key":"1310_CR34","doi-asserted-by":"publisher","unstructured":"Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, et al. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood [Internet]. 2021 [cited 2022 Feb 25];137:2646\u201356. Available from:https:\/\/doi.org\/10.1182\/blood.2020008825","DOI":"10.1182\/blood.2020008825"},{"key":"1310_CR35","doi-asserted-by":"crossref","unstructured":"Iqbal J, Wright G, Wang C, Rosenwald A, Gascoyne RD, Weisenburger DD, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood [Internet]. 2014 [cited 2022 Mar 22];123:2915\u201323. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497120356500","DOI":"10.1182\/blood-2013-11-536359"},{"key":"1310_CR36","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","volume":"124","author":"ER Parrilla Castellar","year":"2014","unstructured":"Parrilla Castellar ER, Jaffe ES, Said JW, Swerdlow SH, Ketterling RP, Knudson RA, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124:1473\u201380.","journal-title":"Blood"},{"key":"1310_CR37","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1111\/bjh.15860","volume":"186","author":"G Hapgood","year":"2019","unstructured":"Hapgood G, Ben-Neriah S, Mottok A, Lee DG, Robert K, Villa D, et al. Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. Br J Haematol. 2019;186:e28-31.","journal-title":"Br J Haematol"},{"key":"1310_CR38","doi-asserted-by":"publisher","unstructured":"Mehta-Shah N, Ito K, Bantilan K, Moskowitz AJ, Sauter C, Horwitz SM, et al. Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma. Blood Advances [Internet]. 2019 [cited 2022 Apr 10];3:187\u201397. Available from:https:\/\/doi.org\/10.1182\/bloodadvances.2018024075","DOI":"10.1182\/bloodadvances.2018024075"},{"key":"1310_CR39","doi-asserted-by":"publisher","unstructured":"Shustov AR, Wilson WH, Beaven AW, Savage KJ, Carson KR, Hernandez-Ilizaliturri FJ, et al. Hepatosplenic T-cell lymphoma: clinicopathological features and treatment outcomes: report from the North American Peripheral T-Cell Lymphoma Consortium. Blood [Internet]. 2013 [cited 2022 May 3];122:3032. Available from: https:\/\/doi.org\/10.1182\/blood.V122.21.3032.3032","DOI":"10.1182\/blood.V122.21.3032.3032"},{"key":"1310_CR40","doi-asserted-by":"publisher","unstructured":"David KA, Pulitzer M, Guitart J, Martinez-Escala ME, Geller S, Wang Y, et al. Characteristics, treatment patterns, and outcomes in primary cutaneous gamma delta T cell lymphoma (PCGDTCL): a real world multi-institutional analysis of a rare malignancy. Blood [Internet]. 2019 [cited 2022 May 7];134:4028. Available from:https:\/\/doi.org\/10.1182\/blood-2019-130223","DOI":"10.1182\/blood-2019-130223"},{"key":"1310_CR41","doi-asserted-by":"crossref","unstructured":"Fuji S, Fujiwara H, Nakano N, Wake A, Inoue Y, Fukuda T, et al. Early application of related SCT might improve clinical outcome in adult T-cell leukemia\/lymphoma. Bone Marrow Transplant [Internet]. Nature Publishing Group; 2016 [cited 2022 May 10];51:205\u201311. Available from: https:\/\/www.nature.com\/articles\/bmt2015265","DOI":"10.1038\/bmt.2015.265"},{"key":"1310_CR42","unstructured":"Miljkovic MD, Melani C, Pittaluga S, Lakhotia R, Lucas N, Jacob A, et al. Next-generation sequencing\u2013based monitoring of circulating tumor DNA reveals clonotypic heterogeneity in untreated PTCL. Blood Adv [Internet]. American Society of Hematology; 2021 [cited 2022 Apr 5];5:4198\u2013210. Available from: http:\/\/ashpublications.org\/bloodadvances\/article\/5\/20\/4198\/476668\/Next-generation-sequencing-based-monitoring-of"},{"key":"1310_CR43","doi-asserted-by":"crossref","unstructured":"Mehta-Shah N, Fehniger TA, Jacobsen ED, Peterson K, Kahl BS, Bartlett NL, et al. End of treatment peripheral blood T-cell receptor gene rearrangement evaluation for minimal residual disease evaluation in peripheral T-cell lymphomas. Blood [Internet]. 2020 [cited 2022 Mar 22];136:30\u20131. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0006497118721174","DOI":"10.1182\/blood-2020-138768"},{"key":"1310_CR44","first-page":"1191","volume":"103","author":"M Bellei","year":"2018","unstructured":"Bellei M, Foss FM, Shustov AR, Horwitz SM, Marcheselli L, Kim WS, et al. The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective. International T-Cell Project Haematologica. 2018;103:1191\u20137.","journal-title":"International T-Cell Project Haematologica"},{"key":"1310_CR45","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000500666","volume":"143","author":"F Lansigan","year":"2020","unstructured":"Lansigan F, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, et al. Outcomes for relapsed and refractory peripheral T-cell lymphoma patients after front-line therapy from the COMPLETE Registry. Acta Haematol. 2020;143:40\u201350.","journal-title":"Acta Haematol"},{"key":"1310_CR46","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","volume":"31","author":"V Mak","year":"2013","unstructured":"Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31:1970\u20136.","journal-title":"J Clin Oncol"},{"key":"1310_CR47","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29:1182\u20139.","journal-title":"J Clin Oncol"},{"key":"1310_CR48","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","volume":"33","author":"OA O\u2019Connor","year":"2015","unstructured":"O\u2019Connor OA, Horwitz S, Masszi T, Van Hoof A, Brown P, Doorduijn J, et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study. J Clin Oncol. 2015;33:2492\u20139.","journal-title":"J Clin Oncol"},{"key":"1310_CR49","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631\u20136.","journal-title":"J Clin Oncol"},{"key":"1310_CR50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-016-0243-8","volume":"9","author":"F Foss","year":"2016","unstructured":"Foss F, Horwitz S, Pro B, Prince HM, Sokol L, Balser B, et al. Romidepsin for the treatment of relapsed\/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol. 2016;9:22.","journal-title":"J Hematol Oncol"},{"key":"1310_CR51","doi-asserted-by":"publisher","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. JCO [Internet]. Wolters Kluwer; 2012 [cited 2022 Apr 5];30:2190\u20136. Available from: https:\/\/ascopubs.org\/doi\/https:\/\/doi.org\/10.1200\/JCO.2011.38.0402","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"1310_CR52","doi-asserted-by":"publisher","unstructured":"Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O\u2019Connor OA, et al. Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood [Internet]. 2014 [cited 2022 Apr 10];123:3095\u2013100. Available from:https:\/\/doi.org\/10.1182\/blood-2013-12-542142","DOI":"10.1182\/blood-2013-12-542142"},{"key":"1310_CR53","doi-asserted-by":"publisher","unstructured":"Hamadani M, Ngoya M, Sureda A, Bashir Q, Litovich CA, Finel H, et al. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. Blood Advances [Internet]. 2022 [cited 2022 Mar 30];6:920\u201330. Available from:https:\/\/doi.org\/10.1182\/bloodadvances.2021005899","DOI":"10.1182\/bloodadvances.2021005899"},{"key":"1310_CR54","doi-asserted-by":"crossref","unstructured":"Castagna L, Pagliardini T, Bramanti S, Schiano de Colella JM, Montes de Oca C, Bouabdallah R, et al. Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome. Bone Marrow Transplant [Internet]. Nature Publishing Group; 2021 [cited 2022 Feb 25];56:883\u20139. Available from: https:\/\/www.nature.com\/articles\/s41409-020-01133-5","DOI":"10.1038\/s41409-020-01133-5"},{"key":"1310_CR55","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.bbmt.2008.04.004","volume":"14","author":"AI Chen","year":"2008","unstructured":"Chen AI, McMillan A, Negrin RS, Horning SJ, Laport GG. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience. Biol Blood Marrow Transplant. 2008;14:741\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1310_CR56","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1200\/JCO.2007.14.1366","volume":"26","author":"S Le Gouill","year":"2008","unstructured":"Le Gouill S, Milpied N, Buzyn A, De Latour RP, Vernant J-P, Mohty M, et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Soci\u00e9t\u00e9 Francaise de Greffe de Mo\u00eblle et de Th\u00e9rapie Cellulaire. J Clin Oncol. 2008;26:2264\u201371.","journal-title":"J Clin Oncol"},{"key":"1310_CR57","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2011.240","volume":"26","author":"A Dodero","year":"2012","unstructured":"Dodero A, Spina F, Narni F, Patriarca F, Cavattoni I, Benedetti F, et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed\/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia. 2012;26:520\u20136.","journal-title":"Leukemia"},{"key":"1310_CR58","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1200\/JCO.2012.46.0188","volume":"31","author":"SM Smith","year":"2013","unstructured":"Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, et al. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. J Clin Oncol. 2013;31:3100\u20139.","journal-title":"J Clin Oncol"},{"key":"1310_CR59","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.bbmt.2015.01.013","volume":"21","author":"A Beitinjaneh","year":"2015","unstructured":"Beitinjaneh A, Saliba RM, Medeiros LJ, Turturro F, Rondon G, Korbling M, et al. Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease. Biol Blood Marrow Transplant. 2015;21:855\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1310_CR60","unstructured":"Mehta-Shah N. Successful treatment of mature T-cell lymphoma with allogeneic stem cell transplantation: the largest multicenter retrospective analysis. ASH; 2020 [cited 2022 Feb 25]. Available from: https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper138542.html"},{"key":"1310_CR61","doi-asserted-by":"publisher","unstructured":"Du J, Yu D, Han X, Zhu L, Huang Z. Comparison of allogeneic stem cell transplant and autologous stem cell transplant in refractory or relapsed peripheral T-cell lymphoma: a systematic review and meta-analysis. JAMA Network Open [Internet]. 2021 [cited 2022 Feb 25];4:e219807. Available from:https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.9807","DOI":"10.1001\/jamanetworkopen.2021.9807"},{"key":"1310_CR62","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/leu.2012.321","volume":"27","author":"S-W Kim","year":"2013","unstructured":"Kim S-W, Yoon S-S, Suzuki R, Matsuno Y, Yi HG, Yoshida T, et al. Comparison of outcomes between autologous and allogeneic hematopoietic stem cell transplantation for peripheral T-cell lymphomas with central review of pathology. Leukemia. 2013;27:1394\u20137.","journal-title":"Leukemia"},{"key":"1310_CR63","doi-asserted-by":"publisher","unstructured":"Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med [Internet]. 2010 [cited 2022 Apr 6];363:2091\u2013101. Available from: http:\/\/www.nejm.org\/doi\/abs\/https:\/\/doi.org\/10.1056\/NEJMoa1004383","DOI":"10.1056\/NEJMoa1004383"},{"key":"1310_CR64","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1093\/annonc\/mdg459","volume":"14","author":"J Rodr\u00edguez","year":"2003","unstructured":"Rodr\u00edguez J, Caballero MD, Guti\u00e9rrez A, Mar\u00edn J, Lahuerta JJ, Sureda A, et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol. 2003;14:1768\u201375.","journal-title":"Ann Oncol"},{"key":"1310_CR65","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/sj.bmt.1705752","volume":"40","author":"S Feyler","year":"2007","unstructured":"Feyler S, Prince HM, Pearce R, Towlson K, Nivison-Smith I, Schey S, et al. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant. 2007;40:443\u201350.","journal-title":"Bone Marrow Transplant"},{"key":"1310_CR66","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/annonc\/mdl466","volume":"18","author":"J Rodr\u00edguez","year":"2007","unstructured":"Rodr\u00edguez J, Conde E, Guti\u00e9rrez A, Arranz R, Le\u00f3n A, Mar\u00edn J, et al. The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol. 2007;18:652\u20137.","journal-title":"Ann Oncol"},{"key":"1310_CR67","first-page":"218","volume":"26","author":"C Kyriakou","year":"2008","unstructured":"Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G, et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26:218\u201324.","journal-title":"J Clin Oncol"},{"key":"1310_CR68","doi-asserted-by":"crossref","unstructured":"Yang D-H, Kim WS, Kim SJ, Bae SH, Kim SH, Kim IH, et al. Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome. Biology of Blood and Marrow Transplantation [Internet]. 2009 [cited 2022 Apr 10];15:118\u201325. Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1083879108005089","DOI":"10.1016\/j.bbmt.2008.11.010"},{"key":"1310_CR69","doi-asserted-by":"crossref","unstructured":"Numata A, Miyamoto T, Ohno Y, Kamimura T, Kamezaki K, Tanimoto T, et al. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant [Internet]. Nature Publishing Group; 2010 [cited 2022 Apr 10];45:311\u20136. Available from: https:\/\/www.nature.com\/articles\/bmt2009165","DOI":"10.1038\/bmt.2009.165"},{"key":"1310_CR70","doi-asserted-by":"publisher","unstructured":"Han X, Zhang W, Zhou D, Ruan J, Duan M, Zhu T, et al. Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: a single-centre experience. J Int Med Res [Internet]. SAGE Publications Ltd; 2017 [cited 2022 Apr 10];45:290\u2013302. Available from:https:\/\/doi.org\/10.1177\/0300060516676725","DOI":"10.1177\/0300060516676725"},{"key":"1310_CR71","doi-asserted-by":"crossref","unstructured":"Wu M, Wang X, Xie Y, Liu W, Zhang C, Ping L, et al. Outcome and prospective factor analysis of high-dose therapy combined with autologous peripheral blood stem cell transplantation in patients with peripheral T-cell lymphomas. Int J Med Sci [Internet]. 2018 [cited 2022 Apr 10];15:867\u201374. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6036090\/","DOI":"10.7150\/ijms.23067"},{"key":"1310_CR72","doi-asserted-by":"publisher","unstructured":"Mamez A-C, Dupont A, Blaise D, Chevallier P, Forcade E, Ceballos P, et al. Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellulaire (SFGM-TC). Journal of Hematology & Oncology [Internet]. 2020 [cited 2022 Feb 25];13:56. Available from:https:\/\/doi.org\/10.1186\/s13045-020-00892-4","DOI":"10.1186\/s13045-020-00892-4"},{"key":"1310_CR73","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1111\/ejh.13465","volume":"105","author":"G McIlroy","year":"2020","unstructured":"McIlroy G, Barmayehvar B, Kamarajah SK, George L, Gondal AZ, Malladi R, et al. Improved outcomes with allogeneic compared with autologous stem cell transplantation in aggressive T-cell lymphoma. Eur J Haematol. 2020;105:514\u20136.","journal-title":"Eur J Haematol"},{"key":"1310_CR74","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41409-018-0360-9","volume":"54","author":"G Wulf","year":"2019","unstructured":"Wulf G, Hasenkamp J, Jung W, Wilhelm C, Held G, Nickelsen M, et al. Allogeneic stem cell transplantation for patients with relapsed or refractory T-cell lymphoma: efficacy of lymphoma-directed conditioning against advanced disease. Bone Marrow Transplant. 2019;54:877\u201384.","journal-title":"Bone Marrow Transplant"},{"key":"1310_CR75","doi-asserted-by":"crossref","unstructured":"Zain J, Palmer JM, Delioukina M, Thomas S, Tsai N-C, Nademanee A, et al. Allogeneic hematopoietic cell transplantation for peripheral T-cell NHL results in long-term disease control. Leuk Lymphoma [Internet]. 2011 [cited 2022 Mar 26];52:1463\u201373. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3441144\/","DOI":"10.3109\/10428194.2011.574754"},{"key":"1310_CR76","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1093\/annonc\/mdq698","volume":"22","author":"ED Jacobsen","year":"2011","unstructured":"Jacobsen ED, Kim HT, Ho VT, Cutler CS, Koreth J, Fisher DC, et al. A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides\/Sezary syndrome. Ann Oncol. 2011;22:1608\u201313.","journal-title":"Ann Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01310-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-022-01310-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-022-01310-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T16:16:47Z","timestamp":1666801007000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-022-01310-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":76,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["1310"],"URL":"https:\/\/doi.org\/10.1007\/s11912-022-01310-3","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,10]]},"assertion":[{"value":"6 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}